|
C1ORF52 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.30050414881566E-11 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.68410000389585E-08 |
| Normal-vs-Stage2 |
1.19930000375135E-08 |
| Normal-vs-Stage3 |
4.02329947135627E-10 |
| Normal-vs-Stage4 |
8.3262952088603E-11 |
| Stage1-vs-Stage2 |
4.711900E-02 |
| Stage1-vs-Stage3 |
1.205510E-02 |
| Stage1-vs-Stage4 |
4.815800E-03 |
| Stage2-vs-Stage3 |
9.504800E-01 |
| Stage2-vs-Stage4 |
5.263600E-01 |
| Stage3-vs-Stage4 |
4.645600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
6.572298261176E-11 |
| Normal-vs-AfricanAmerican |
1.614580E-04 |
| Normal-vs-Asian |
3.1200000000231E-06 |
| Caucasian-vs-AfricanAmerican |
8.638800E-01 |
| Caucasian-vs-Asian |
6.951400E-01 |
| AfricanAmerican-vs-Asian |
9.152400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.90260029953038E-10 |
| Normal-vs-Female |
1.29530053349924E-10 |
| Male-vs-Female |
4.073000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.11200000044265E-07 |
| Normal-vs-Age(41-60Yrs) |
6.35510533086858E-11 |
| Normal-vs-Age(61-80Yrs) |
3.10530490210681E-11 |
| Normal-vs-Age(81-100Yrs) |
7.762900E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.339810E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
6.555600E-03 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.339600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
5.873200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.329800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.758200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.116930E-03 |
| Classical-VS-Follicular |
1.650390E-01 |
| Classical-VS-Other |
8.812200E-01 |
| Classical-VS-Normal |
1.29050004016307E-09 |
| Tall-VS-Follicular |
1.193410E-01 |
| Tall-VS-Other |
2.562000E-01 |
| Tall-VS-Normal |
2.06849981587709E-10 |
| Follicular-VS-Other |
5.862000E-01 |
| Follicular-VS-Normal |
1.79709999992284E-07 |
| Other-VS-Normal |
4.644200E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
4.7940995617779E-10 |
| Normal-vs-N1 |
5.06569999947359E-07 |
| N0-vs-N1 |
9.597200E-01 |
|
|
